从LEAP试验系列中学习:优化组合疗法的临床试验设计
Jiatong Ding1, Yue Yu1, Dandan Cui1
1Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Med (New York, N.Y.)
|May 10, 2025
概括
在LEAP试验中,在癌症治疗中结合pembrolizumab和lenvatinib的结果不一. 需要进一步的研究来优化这些组合疗法,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 在LEAP试验系列中,研究了pembrolizumab和lenvatinib的组合.
- 这些试验跨越多种癌症类型,评估协同效应.
研究的目的:
- 分析LEAP试验系列的结果.
- 确定结合癌症治疗策略中需要改进的领域.
- 推进开发有效的治疗组合.
主要方法:
- 从LEAP试验系列的数据的审查.
- 对 pembrolizumab 和 lenvatinib 组合的疗效和安全性的分析.
- 确定影响治疗结果的因素.
主要成果:
- 在LEAP试验中,pembrolizumab-lenvatinib组合在不同癌症中表现出不同的疗效.
- 结果表明需要更深入地了解这些药物之间的协同作用.
- 混合结果需要进一步调查患者选择和治疗方案.
结论:
- 潘布罗利祖马布和伦瓦提尼布的协同作用需要进一步阐明.
- 优化组合策略对于改善瘤学患者的治疗结果至关重要.
- 未来的研究应该集中在完善基于试验学习的组合疗法方法.
相关概念视频
Clinical Trials: Overview
2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K
Crossover Experiments
2.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.7K
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Hazard Ratio
69
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
69
Preclinical Development: Overview
4.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.0K


